Thoughts on How to Implement Good Pharmacovigilance Practices in China from a Global Pharmaceutical Industry Perspective

doi:10.19803/j.1672-8629.2021.06.03

Abstract

Abstract: Objective To explore the approaches to perform life-cycle pharmacovigilance and to implement Good Pharmacovigilance Practices (GVP) in order to fulfil the regulatory requirements in China from an industry perspective. Methods Based on the empirical data from global pharmaceutical companies, a systematic approach was taken to assess the current status of implementing GVP and make practical recommendations to the key steps of implementation of the regulation. Results and Conclusion The implementation of GVP is critical and essential to enhance pharmacovigilance system in pharmaceutical industry.

Key words: pharmacovigilance, good pharmacovigilance practices, pharmacovigilance system, quality management

CLC Number:

R951

ZHANG Yijing. Thoughts on How to Implement Good Pharmacovigilance Practices in China from a Global Pharmaceutical Industry Perspective[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 507-509.

References

[1] WHO. The Importance of pharmacovigilance: safety monitoring of medical products. publications of world health organization, 2002[EB/OL].( 2002-01-01)[2021-03-13].https://www.who.int/publications/i/item/10665-42493.
[2] Standing Committee of the National People's Congress. Drug Administration Law of the People's Republic of China[EB/OL].(2019-08-26)[2021-03-13]. http://www.gov.cn/xinwen/ 2019-08/26/content_5424780.htm.
[3] NMPA. NMPA announcement on issuing good pharmacovigilance practices (No.65 of2021)[EB/OL].(2021-05-13)[2021-05-13].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210513151827179.html.
[4] EMA. EMA GVP module 1- Pharmacovigilance systems and their quality systems[EB/OL].(2012-06-22)[2021-03-23]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf.
[5] EMA. EMA GVP module 2- Pharmacovigilance system master file (Rev 2) [EB/OL].(2017-03-28)[2021-03-21].https://www.ema. europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-ii-pharmacovigilance-system-master-file-rev-2_en.pdf.
[6] ICH. ICH E2A Clinical safety data management: definitions and standards for Expedited reporting[EB/OL].(1994-10-27)[2021-03-21]. https://database.ich.org/sites/default/files/E2A_Guideline.pdf.
[7] ICH. ICH E2D Post-approval safety data managem-ent: Definitions and standards for expedited reporting[EB/OL].(2003-11-12)[2021-03-20].https://database.ich.org/sites/default/files/E2D_Guideline.pdf.
[8] ICH. ICH E2E Pharmacovigilance planning[EB/OL].(2004-11-18)[2021-02-19]. https://database.ich.org/sites/default/files/E2E_Guideline.pdf.
[9] ICH. ICH E2C (R2) Periodic benefit-risk evaluation report (pbrer)[EB/OL].(2012-12-17)[2021-01-11].https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf.
[10] ICH. ICH E2F Development safety update report[EB/OL].(2010-08-17)[2021-01-17]. https://database.ich.org/sites/default/files/E2F_Guideline.pdf.

[1]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[2]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[3]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[4]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[5]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[9]	HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
[10]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[11]	PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
[12]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[13]	WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong. Current applications of artificial intelligence in pharmacovigilance in the USA and implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
[14]	ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia. Thyroid immune-related adverse reactions of immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
[15]	JIANG Hao, ZHANG Bing, ZHANG Xiaomeng, LIN Zhijian, LYU Jintao, ZHANG Dan. Descriptions of pharmacovigilance in materia medica works of Sui, Tang and the Five Dynasties [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 987-993.